Immunohistochemical study of VEGF-A, VEGFR-1, VEGFR-2 and CD34 expression in сolorectal adenocarcinoma progression
DOI:
https://doi.org/10.14739/2310-1237.2019.2.177075Keywords:
colorectal cancer, neovascularization, pathologic, Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor Receptor-1, Vascular Endothelial Growth Factor Receptor-2, CD34 AntigenAbstract
Aim – to study VEGF-A, VEGFR-1, VEGFR-2 and CD34 immunohistochemical expression on the I, II, III, IV stages (pTNM) of colorectal adenocarcinoma development.
Materials and methods. Pathomorphological and immunohistochemical studies of surgical material of colorectal adenocarcinoma (CRA) from 40 patients (I, II, III and IV stages, 10 cases in each group) were conducted.
Results. There is a tendency to increasing expression of VEGF-A and VEGFR-2 during the CRA progression from I to IV stage (VEGF-A 37.80 (30.22; 56.89) CUOD on I stage, 88.50 (63.00 ; 115.00) CUOD on II stage, 79.34 (63.14; 84.99) CUOD on III stage, 84.69 (80.66; 110.28) CUOD on IV stage; VEGFR-2 – 52.75 (39.14; 70.22) CUOD on I stage, 82.71 (63.14; 111.19) CUOD on II stage, 104.17 (96.04; 111.02) CUOD on III stage, 99.91 (86.15; 120.29) CUOD on IV stage). The expression indices of these markers correlate in CRA stages I, II and III (r = 0.95, r = 0.69, r = 0.85). It is established that VEGFR-1 is not expressed in unchanged mucous membrane of the large intestine, as well as in samples of CRA stage I. On subsequent II, III and IV stages of CRA progresson the marker is expressed by stromal cells, but there is an absence of statistically significant difference between the expression indices. There are no correlations between expression indices of VEGFR-1 and other studied markers. The microvascular density assessed by CD34 expression is not significantly different on each of CRA progression stages. There are direct correlations between microvascular density and VEGF-A expression (r = 0.70), and VEGFR-2 expression (r = 0.69) in CRA III stage, microvascular density and VEGF-A expression in CRA IV stage (r = 0.69).
Conclusions. Expression of VEGF-A and VEGFR-2 increases with the progression of colorectal adenocarcinoma from stage I to stage IV, with a maximum “jump” of the expression levels from stage I to stage II of colorectal adenocarcinoma, which may be due to abnormally increasing KRAS activity.
References
Kawada, K., Hasegawa, S., Murakami, T., Itatani, Y., Hosogi, H., Sonoshita, M., et al. (2011) Molecular mechanisms of liver metastasis. International Journal of Clinical Oncology, 16(5), 464–472. doi: 10.1007/s10147-011-0307-2
Langrand-Escure, J., Diao, P., Garcia, M.-A., Wang, G., Guy, J.-B., Espenel, S., et al. (2018) Outcome and prognostic factors in 593 non-metastatic rectal cancer patients: a mono-institutional survey. Scientific Reports, 8(1), 10708. doi: 10.1038/s41598-018-29040-2
Sun, W. (2012) Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy. Journal of Hematology & Oncology, 5, 63. doi: 10.1186/1756-8722-5-63
Liu, Z., Qi, L., Li, Y., Zhao, X., & Sun, B. (2017) VEGFR2 regulates endothelial differentiation of colon cancer cells. BMC Cancer, 17(1), 593. doi: 10.1186/s12885-017-3578-9
Jeong, E. H., Kim, Y., Min, B. W., Lee, K. H., Kim, H. S., & Lee, J. H. (2010) Differences in Expression of VEGF-A, VEGFR-1, VEGFR-2 and Microvessel Density in Colorectal Cancer with Liver Metastasis. Journal of Pathology and Translational Medicine, 44(6), 571–580. doi: 10.4132/KoreanJPathol.2010.44.6.571
Valverde, A., Penarando, J., Canas, A., Lopez-Sanchez, L. M., Conde, F., Hernandes, V., et al. (2015) Simultaneous Inhibition of EGFR/VEGFR and Cyclooxygenase-2 Targets Stemness-Related Pathways in Colorectal Cancer Cells. PLoS One, 10(6), e0131363. doi: 10.1371/journal.pone.0131363
Tournigand, C., Chibaudel, B., Samson, B., Scheithauer, W., Vernerey, D., Mesange P., et al. (2015) Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (gercor dream; optimox3): A randomised, open-label, phase 3 trial. Lancet Oncology, 16(15), 1493–505. doi: 10.1016/S1470-2045(15)00216-8
Canavese, M., Ngo, D. T., Maddern, G. J., Hardingham, J. E., Price, T. J., & Hauben, E. (2017) Biology and therapeutic implications of VEGF-A splice isoforms and single-nucleotide polymorphisms in colorectal cancer. International Journal of Cancer, 140(10), 2183–2191. doi: 10.1002/ijc.30567
D’Haene, N., Koopmansch, C., Van Eycke, Y.-R., Hulet. F., Allard, J., Bouri, S., et al. (2018) The Prognostic Value of the Combination of Low VEGFR-1 and High VEGFR-2 Expression in Endothelial Cells of Colorectal Cancer. International Journal of Molecular Sciences, 19(11), 3536. doi: 10.3390/ijms19113536
Deliu, I. C., Neagoe, C. D., Bezna, M., Genunche-Dumitrescu, A. V., Toma, S. C., Ungureanu, B. S., et al. (2016) Correlations between endothelial cell markers CD31, CD34 and CD105 in colorectal carcinoma. Romanian Journal of Morphology and Embriology, 57(3), 1025–1030.
Toma, S. C., Uscatu, C. D., Ungureanu, B. S., Mirea, C. S., Dumitrescu, T., Georgescu, E. F., et al. (2018) Correlations between CD34 Immunolabelled Blood Vessels and CD34 mRNA Expression in Colorectal Cancer. Current Health Sciences Journal, 44(1), 60–63. doi: 10.12865/CHSJ.44.01.10
Ding, C., Li, L., Yang, T., Fan, X., & Wu, G. (2016) Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model. BMC Cancer, 16(1), 791. doi: 10.1186/s12885-016-2834-8
Bhattacharya, R., Ye, X. C., Wang, R., Ling, X., McManus, M., Fan, F., Boulbes, D., & Ellis, L.M. (2016) Intracrine VEGF signaling mediates the activity of prosurvival pathways in human colorectal cancer cells. Cancer Research, 76(10), 3014–3024. doi: 10.1158/0008-5472.CAN-15-1605
Samuel, S., Fan, F., Dang, L. H., Xia, L., Gaur, P., & Ellis, L.M. (2011) Intracrine vascular endothelial growth factor signaling in survival and chemoresistance of human colorectal cancer cells. Oncogene, 30(10), 1205–1212. doi: 10.1038/onc.2010.496
Kimura, Y., Morohashi, S., Yoshizawa, T., Suzuki, T., Morohashi, H., Sakamoto, Y., et al. (2016) Clinicopathological significance of vascular endothelial growth factor, thymidine phosphorylase and microvessel density in colorectal cancer. Molecular Medicine Reports, 13(2), 1551–1557. doi: 10.3892/mmr.2015.4687
Sobin, L. H., Gospodarowicz, M. K., & Wittekind, C. (2009) International Union Against Cancer (UICC): TNM Classification of Malignant Tumours. New York: Wiley-Blackwell.
Bosari, S., Lee, A. K., DeLellis, R. A., Wiley, B. D., Heatley, G. J., & Silverman, M. L. (1992) Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol., 23(7), 755–61. doi: 10.1016/0046-8177(92)90344-3
Shyshkin, M. A. (2018) Molekulyarno-immunogistokhimicheskaya kharakteristika proliferacii i apoptoza opukholevykh kletok kolorektal'noj adenokarcinomy [Molecular-immunohistochemical characteristics of proliferation and apoptosis of tumor cells in colorectal adenocarcinoma]. Pathologia, 15(1), 49–56. doi: 10.14739/2310-1237. 2018.1.129447
Margetis, N., Kouloukoussa, M., Pavlou, K., Vrakas, S., & Mariolis-Sapsakos, T. (2017) K-ras Mutations as the Earliest Driving Force in a Subset of Colorectal Carcinomas. In vivo, 31(4), 527–542. doi: 10.21873/invivo.11091
Tumanskiy, V. A., Chepets, A. V., & Kamyshnyi, A. M. (2016) Comparative characteristics of the transcriptional activity of CDH1, CTNNB1, VEGFA genes and expression of proteins E-cadherin, β-catenin and VEGFA, coded by these genes in metastatic and non-metastatic endometrioid endometrial carcinoma. Pathologia, 2(37), 13–18. doi: 10.14739/2310-1237.2016.2.81328
Mody, K., Baldeo, C., & Bekaii-Saab, T. (2018) Antiangiogenic Therapy in Colorectal Cancer. Cancer Journal, 24(4), 165–170. doi: 10.1097/PPO.0000000000000328
Wu, M. H., Ying, N. W., Hong, T. M., Chiang, W. F., Lin, Y. T., & Chen, Y. L. (2014) Galectin-1 induces vascular permeability through the neuropilin-1/vascular endothelial growth factor receptor-1 complex. Angiogenesis, 17(4), 839–849. doi: 10.1007/s10456-014-9431-8
Eppenberger, M., Zlobec, I., Baumhoer, D., Terracciano, L., & Lugli, A. (2010) Role of the VEGF ligand to receptor ratio in the progression of mismatch repair-proficient colorectal cancer. BMC Cancer, 10, 93. doi: 10.1186/1471-2407-10-93
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).
